Protocol No. A2581087: The Achieve Cholesterol Targets Fast With Atorvastatin Stratified Titration (ACTFAST) Study. A Multicenter, Twelve-Week Treatment, Single Step Titration, Open-Label Study Assessing The Percentage Of Dyslipidemic High-Risk Patients Achieving Low Density Lipoprotein Cholesterol Targets (LDL-C) With Atorvastatin Starting Doses Of 10 mg, 20 mg, 40 mg, and 80 mg.
de Teresa E, Farsang C, Gaw A, et al. Achieve cholesterol targets fast with atorvastatin stratified titration: the ACTFAST study [abstract]. Atherosclerosis Suppl. 2004; 5(suppl 1):115. Abstract M.500.
Langer A, de Teresa E, Farsang C. et al. Achieve cholesterol targets fast with atorvastatin stratified titration: the ACTFAST study [abstract]. In: Abstracts of the XV International Symposium on Drugs Affecting Lipid Metabolism; October 24-27, 2004; Venice, Italy. 144.
Martineau P, Gaw A, de Teresa E, et al. Effect of individualizing starting doses of a statin according to baseline LDL-cholesterol levels on achieving cholesterol targets: the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST) study. Atherosclerosis [serial online]. In Press. Available at: <http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6T12-4JTRTDT-1&_coverDate=04%2F27%2F2006&_alid=397356926&_rdoc=1&_fmt=&_orig=search&_qd=1&_cdi=4878&_sort=d&view=c&_acct=C000000313&_version=1&_urlVersion=0&_userid=89898&md5=640aa457e859e1a7b25476609d92a834> Accessed July 31, 2006.
Link to ClinicalTrials.gov registration: http://clinicaltrials.gov/show/NCT00442845
Pfizer will use reasonable efforts to include accurate and up-to-date information on the ClinicalStudyResults.org web site. However, because the status of studies often changes, Pfizer can make no, and makes no, warranties or representations of any kind as to the currency or completeness of the information contained therein. You agree that access to and use of information posted by Pfizer on the ClinicalStudyResults.org web site is at your own risk. Pfizer disclaims all warranties, express or implied, including warranties of merchantability of fitness for a particular purpose. Pfizer shall not be liable for any damages, including without limitation, direct, incidental, consequential, indirect or punitive damages, arising out of access to, use of, or inability to use information posted by Pfizer on the ClinicalStudyResults.org web site, or any errors or omissions in the content thereof. The ClinicalStudyResults.org web site is maintained by PhRMA, a trade association of which Pfizer is a member. PhRMA had no role in the sponsorship or conduct of the studies posted by Pfizer on ClinicalStudyResults.org.
|
